Rituximab And Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options In Patients With Low-Grade Lymphoma Of The Orbit
BLOOD(2005)
Abstract
Objective: To report a cohort of patients with lymphoid tumors of the orbit, including 1 with benign lymphoid hyperplasia of the orbit whose disease responded to immunotherapy with rituximab alone or rituximab followed by Zevalin (yttrium-90 ibritumomab tiuxetan) radioimmunotherapy.
MoreTranslated text
Key words
lymphoma,radioimmunotherapy,rituximab,low-grade
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined